Review



massive parallel sequencing  (Complete Genomics Inc)


Bioz Verified Symbol Complete Genomics Inc is a verified supplier
Bioz Manufacturer Symbol Complete Genomics Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    Complete Genomics Inc massive parallel sequencing
    Genetic and clinical summary of KBG syndrome. Genetic findings (left panel) showing variant characteristics (c.1977C>G; p.Tyr659Ter), American College of Medical Genetics and Genomics classification (PVS1, PM2, PP5), <t>sequencing</t> methodology and ANKRD11 protein structure with functional domains. The schematic illustrates the location of the truncating variant at position 659, resulting in loss of 75% of the protein including the repression domain, activation domain and C-terminal region. Clinical summary (right panel) consolidating developmental milestones, growth parameters, clinical features across multiple systems, key investigations and management outcomes after 24 months of follow-up. RD = repression domain; AD = activation domain .
    Massive Parallel Sequencing, supplied by Complete Genomics Inc, used in various techniques. Bioz Stars score: 99/100, based on 590 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/massive parallel sequencing/product/Complete Genomics Inc
    Average 99 stars, based on 590 article reviews
    massive parallel sequencing - by Bioz Stars, 2026-06
    99/100 stars

    Images

    1) Product Images from "Novel ANKRD11 Mutation in KBG Syndrome: A diagnostic triad of hearing loss, radiological macrodontia and artificial intelligence-assisted facial phenotyping"

    Article Title: Novel ANKRD11 Mutation in KBG Syndrome: A diagnostic triad of hearing loss, radiological macrodontia and artificial intelligence-assisted facial phenotyping

    Journal: Sultan Qaboos University Medical Journal

    doi: 10.18295/2075-0528.2963

    Genetic and clinical summary of KBG syndrome. Genetic findings (left panel) showing variant characteristics (c.1977C>G; p.Tyr659Ter), American College of Medical Genetics and Genomics classification (PVS1, PM2, PP5), sequencing methodology and ANKRD11 protein structure with functional domains. The schematic illustrates the location of the truncating variant at position 659, resulting in loss of 75% of the protein including the repression domain, activation domain and C-terminal region. Clinical summary (right panel) consolidating developmental milestones, growth parameters, clinical features across multiple systems, key investigations and management outcomes after 24 months of follow-up. RD = repression domain; AD = activation domain .
    Figure Legend Snippet: Genetic and clinical summary of KBG syndrome. Genetic findings (left panel) showing variant characteristics (c.1977C>G; p.Tyr659Ter), American College of Medical Genetics and Genomics classification (PVS1, PM2, PP5), sequencing methodology and ANKRD11 protein structure with functional domains. The schematic illustrates the location of the truncating variant at position 659, resulting in loss of 75% of the protein including the repression domain, activation domain and C-terminal region. Clinical summary (right panel) consolidating developmental milestones, growth parameters, clinical features across multiple systems, key investigations and management outcomes after 24 months of follow-up. RD = repression domain; AD = activation domain .

    Techniques Used: Variant Assay, Sequencing, Functional Assay, Activation Assay



    Similar Products

    99
    Complete Genomics Inc massive parallel sequencing
    Genetic and clinical summary of KBG syndrome. Genetic findings (left panel) showing variant characteristics (c.1977C>G; p.Tyr659Ter), American College of Medical Genetics and Genomics classification (PVS1, PM2, PP5), <t>sequencing</t> methodology and ANKRD11 protein structure with functional domains. The schematic illustrates the location of the truncating variant at position 659, resulting in loss of 75% of the protein including the repression domain, activation domain and C-terminal region. Clinical summary (right panel) consolidating developmental milestones, growth parameters, clinical features across multiple systems, key investigations and management outcomes after 24 months of follow-up. RD = repression domain; AD = activation domain .
    Massive Parallel Sequencing, supplied by Complete Genomics Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/massive parallel sequencing/product/Complete Genomics Inc
    Average 99 stars, based on 1 article reviews
    massive parallel sequencing - by Bioz Stars, 2026-06
    99/100 stars
      Buy from Supplier

    86
    Novogene massive parallel sequencing
    A) Scheme showing the functional domains of p53, with the location of CASM34 mutants indicated in the zoomed-in panel. Transactivation (TAD) domain; proline-rich domain (PRD); DNA binding domain (DBD); oligomerization domain (OD); C-terminal domain (CTD). B and C) . Circular plots showing the base-pairing potentials of the p53 mRNA coding <t>sequence</t> (CDS) based on SHAPE reactivity with (B) p53-WT and (C) CASM34 (c.102 C>A) expressed in p53 null H1299 cells. Base-pairing across the nucleotides are indicated by lines and modifications in the lining pattern indicate RNA secondary structure alterations. RNA Regions which are significantly modified in secondary structure in CASM34 are indicated with dashed orange oval. D) and E) Secondary structures of indicated p53 mRNAs coding sequences using the SuperFold algorithm based on SHAPE values. SHAPE modified nucleotide sequences are indicated in orange and red. F) ΔSHAPE analysis demonstrates significant structural variations in the p53 mRNA CDS between p53-WT and CASM34 (c.102 C>A) mutant, with RNA regions constrained in CASM34 (c.102 C>A) are highlighted in green and the regions opened or exposed highlighted in violet. G) Same as (D) and (E) based on SHAPE values with CASM34 (c.102 C>G) mutant. SHAPE-Map data shown are representative of at least two independent repeats. RNA secondary structure models of p53-WT, showed in B) and D)are extracted from
    Massive Parallel Sequencing, supplied by Novogene, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/massive parallel sequencing/product/Novogene
    Average 86 stars, based on 1 article reviews
    massive parallel sequencing - by Bioz Stars, 2026-06
    86/100 stars
      Buy from Supplier

    90
    Illumina Inc fragment libraries for massively parallel sequencing
    A) Scheme showing the functional domains of p53, with the location of CASM34 mutants indicated in the zoomed-in panel. Transactivation (TAD) domain; proline-rich domain (PRD); DNA binding domain (DBD); oligomerization domain (OD); C-terminal domain (CTD). B and C) . Circular plots showing the base-pairing potentials of the p53 mRNA coding <t>sequence</t> (CDS) based on SHAPE reactivity with (B) p53-WT and (C) CASM34 (c.102 C>A) expressed in p53 null H1299 cells. Base-pairing across the nucleotides are indicated by lines and modifications in the lining pattern indicate RNA secondary structure alterations. RNA Regions which are significantly modified in secondary structure in CASM34 are indicated with dashed orange oval. D) and E) Secondary structures of indicated p53 mRNAs coding sequences using the SuperFold algorithm based on SHAPE values. SHAPE modified nucleotide sequences are indicated in orange and red. F) ΔSHAPE analysis demonstrates significant structural variations in the p53 mRNA CDS between p53-WT and CASM34 (c.102 C>A) mutant, with RNA regions constrained in CASM34 (c.102 C>A) are highlighted in green and the regions opened or exposed highlighted in violet. G) Same as (D) and (E) based on SHAPE values with CASM34 (c.102 C>G) mutant. SHAPE-Map data shown are representative of at least two independent repeats. RNA secondary structure models of p53-WT, showed in B) and D)are extracted from
    Fragment Libraries For Massively Parallel Sequencing, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fragment libraries for massively parallel sequencing/product/Illumina Inc
    Average 90 stars, based on 1 article reviews
    fragment libraries for massively parallel sequencing - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    99
    Illumina Inc massive parallel sequencing
    PPM1D variants associated with Jansen-de Vries syndrome reported in the literature, in this case (red square), and in the ClinVar database to date ( https://www.ncbi.nlm.nih.gov/clinvar/ ). [1] ; [2] ; [3] ; [4] ; [5] ; [6] ; [7] ; [8] ; [9] ; [10] ; [11] ; [12] ; [13] ClinVar . Reference <t>sequence</t> NM_003620.4 .
    Massive Parallel Sequencing, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/massive parallel sequencing/product/Illumina Inc
    Average 99 stars, based on 1 article reviews
    massive parallel sequencing - by Bioz Stars, 2026-06
    99/100 stars
      Buy from Supplier

    90
    Illumina Inc whole-genome massively parallel sequencing
    PPM1D variants associated with Jansen-de Vries syndrome reported in the literature, in this case (red square), and in the ClinVar database to date ( https://www.ncbi.nlm.nih.gov/clinvar/ ). [1] ; [2] ; [3] ; [4] ; [5] ; [6] ; [7] ; [8] ; [9] ; [10] ; [11] ; [12] ; [13] ClinVar . Reference <t>sequence</t> NM_003620.4 .
    Whole Genome Massively Parallel Sequencing, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/whole-genome massively parallel sequencing/product/Illumina Inc
    Average 90 stars, based on 1 article reviews
    whole-genome massively parallel sequencing - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    90
    Illumina Inc massively parallel dna sequencing platforms
    PPM1D variants associated with Jansen-de Vries syndrome reported in the literature, in this case (red square), and in the ClinVar database to date ( https://www.ncbi.nlm.nih.gov/clinvar/ ). [1] ; [2] ; [3] ; [4] ; [5] ; [6] ; [7] ; [8] ; [9] ; [10] ; [11] ; [12] ; [13] ClinVar . Reference <t>sequence</t> NM_003620.4 .
    Massively Parallel Dna Sequencing Platforms, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/massively parallel dna sequencing platforms/product/Illumina Inc
    Average 90 stars, based on 1 article reviews
    massively parallel dna sequencing platforms - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    90
    Novogene massive parallel amplicon sequencing
    PPM1D variants associated with Jansen-de Vries syndrome reported in the literature, in this case (red square), and in the ClinVar database to date ( https://www.ncbi.nlm.nih.gov/clinvar/ ). [1] ; [2] ; [3] ; [4] ; [5] ; [6] ; [7] ; [8] ; [9] ; [10] ; [11] ; [12] ; [13] ClinVar . Reference <t>sequence</t> NM_003620.4 .
    Massive Parallel Amplicon Sequencing, supplied by Novogene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/massive parallel amplicon sequencing/product/Novogene
    Average 90 stars, based on 1 article reviews
    massive parallel amplicon sequencing - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    99
    Illumina Inc nonstranded rna seq massively parallel mrna sequencing approach
    PPM1D variants associated with Jansen-de Vries syndrome reported in the literature, in this case (red square), and in the ClinVar database to date ( https://www.ncbi.nlm.nih.gov/clinvar/ ). [1] ; [2] ; [3] ; [4] ; [5] ; [6] ; [7] ; [8] ; [9] ; [10] ; [11] ; [12] ; [13] ClinVar . Reference <t>sequence</t> NM_003620.4 .
    Nonstranded Rna Seq Massively Parallel Mrna Sequencing Approach, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nonstranded rna seq massively parallel mrna sequencing approach/product/Illumina Inc
    Average 99 stars, based on 1 article reviews
    nonstranded rna seq massively parallel mrna sequencing approach - by Bioz Stars, 2026-06
    99/100 stars
      Buy from Supplier

    90
    Nextera AS massive parallel sequencing nextera rapid capture
    PPM1D variants associated with Jansen-de Vries syndrome reported in the literature, in this case (red square), and in the ClinVar database to date ( https://www.ncbi.nlm.nih.gov/clinvar/ ). [1] ; [2] ; [3] ; [4] ; [5] ; [6] ; [7] ; [8] ; [9] ; [10] ; [11] ; [12] ; [13] ClinVar . Reference <t>sequence</t> NM_003620.4 .
    Massive Parallel Sequencing Nextera Rapid Capture, supplied by Nextera AS, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/massive parallel sequencing nextera rapid capture/product/Nextera AS
    Average 90 stars, based on 1 article reviews
    massive parallel sequencing nextera rapid capture - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    Image Search Results


    Genetic and clinical summary of KBG syndrome. Genetic findings (left panel) showing variant characteristics (c.1977C>G; p.Tyr659Ter), American College of Medical Genetics and Genomics classification (PVS1, PM2, PP5), sequencing methodology and ANKRD11 protein structure with functional domains. The schematic illustrates the location of the truncating variant at position 659, resulting in loss of 75% of the protein including the repression domain, activation domain and C-terminal region. Clinical summary (right panel) consolidating developmental milestones, growth parameters, clinical features across multiple systems, key investigations and management outcomes after 24 months of follow-up. RD = repression domain; AD = activation domain .

    Journal: Sultan Qaboos University Medical Journal

    Article Title: Novel ANKRD11 Mutation in KBG Syndrome: A diagnostic triad of hearing loss, radiological macrodontia and artificial intelligence-assisted facial phenotyping

    doi: 10.18295/2075-0528.2963

    Figure Lengend Snippet: Genetic and clinical summary of KBG syndrome. Genetic findings (left panel) showing variant characteristics (c.1977C>G; p.Tyr659Ter), American College of Medical Genetics and Genomics classification (PVS1, PM2, PP5), sequencing methodology and ANKRD11 protein structure with functional domains. The schematic illustrates the location of the truncating variant at position 659, resulting in loss of 75% of the protein including the repression domain, activation domain and C-terminal region. Clinical summary (right panel) consolidating developmental milestones, growth parameters, clinical features across multiple systems, key investigations and management outcomes after 24 months of follow-up. RD = repression domain; AD = activation domain .

    Article Snippet: Massive parallel sequencing was conducted on the DNBSEQ-G400 platform (MGI).

    Techniques: Variant Assay, Sequencing, Functional Assay, Activation Assay

    A) Scheme showing the functional domains of p53, with the location of CASM34 mutants indicated in the zoomed-in panel. Transactivation (TAD) domain; proline-rich domain (PRD); DNA binding domain (DBD); oligomerization domain (OD); C-terminal domain (CTD). B and C) . Circular plots showing the base-pairing potentials of the p53 mRNA coding sequence (CDS) based on SHAPE reactivity with (B) p53-WT and (C) CASM34 (c.102 C>A) expressed in p53 null H1299 cells. Base-pairing across the nucleotides are indicated by lines and modifications in the lining pattern indicate RNA secondary structure alterations. RNA Regions which are significantly modified in secondary structure in CASM34 are indicated with dashed orange oval. D) and E) Secondary structures of indicated p53 mRNAs coding sequences using the SuperFold algorithm based on SHAPE values. SHAPE modified nucleotide sequences are indicated in orange and red. F) ΔSHAPE analysis demonstrates significant structural variations in the p53 mRNA CDS between p53-WT and CASM34 (c.102 C>A) mutant, with RNA regions constrained in CASM34 (c.102 C>A) are highlighted in green and the regions opened or exposed highlighted in violet. G) Same as (D) and (E) based on SHAPE values with CASM34 (c.102 C>G) mutant. SHAPE-Map data shown are representative of at least two independent repeats. RNA secondary structure models of p53-WT, showed in B) and D)are extracted from

    Journal: bioRxiv

    Article Title: Cancer-associated synonymous mutations reveal stress signal-dependent mRNA folding that selectively modulates protein function

    doi: 10.64898/2026.01.26.701754

    Figure Lengend Snippet: A) Scheme showing the functional domains of p53, with the location of CASM34 mutants indicated in the zoomed-in panel. Transactivation (TAD) domain; proline-rich domain (PRD); DNA binding domain (DBD); oligomerization domain (OD); C-terminal domain (CTD). B and C) . Circular plots showing the base-pairing potentials of the p53 mRNA coding sequence (CDS) based on SHAPE reactivity with (B) p53-WT and (C) CASM34 (c.102 C>A) expressed in p53 null H1299 cells. Base-pairing across the nucleotides are indicated by lines and modifications in the lining pattern indicate RNA secondary structure alterations. RNA Regions which are significantly modified in secondary structure in CASM34 are indicated with dashed orange oval. D) and E) Secondary structures of indicated p53 mRNAs coding sequences using the SuperFold algorithm based on SHAPE values. SHAPE modified nucleotide sequences are indicated in orange and red. F) ΔSHAPE analysis demonstrates significant structural variations in the p53 mRNA CDS between p53-WT and CASM34 (c.102 C>A) mutant, with RNA regions constrained in CASM34 (c.102 C>A) are highlighted in green and the regions opened or exposed highlighted in violet. G) Same as (D) and (E) based on SHAPE values with CASM34 (c.102 C>G) mutant. SHAPE-Map data shown are representative of at least two independent repeats. RNA secondary structure models of p53-WT, showed in B) and D)are extracted from

    Article Snippet: RNAs were then subjected to polyA purification, library preparation and massive parallel sequencing (Novogene, UK).

    Techniques: Functional Assay, Binding Assay, Sequencing, Modification, Mutagenesis

    A) Volcano plot showing changes in expression levels of genome-wide transcripts in H1299 cells expressing p53-WT and CASM34 (c. 102 C>A) based on RNA-seq data of at least two independent replicates. B and C) Gene enrichment analysis of RNA-sequencing data categorizing the altered transcripts level following expression of p53-WT or CASM34 (c. 102 C>A) mRNAs.

    Journal: bioRxiv

    Article Title: Cancer-associated synonymous mutations reveal stress signal-dependent mRNA folding that selectively modulates protein function

    doi: 10.64898/2026.01.26.701754

    Figure Lengend Snippet: A) Volcano plot showing changes in expression levels of genome-wide transcripts in H1299 cells expressing p53-WT and CASM34 (c. 102 C>A) based on RNA-seq data of at least two independent replicates. B and C) Gene enrichment analysis of RNA-sequencing data categorizing the altered transcripts level following expression of p53-WT or CASM34 (c. 102 C>A) mRNAs.

    Article Snippet: RNAs were then subjected to polyA purification, library preparation and massive parallel sequencing (Novogene, UK).

    Techniques: Expressing, Genome Wide, RNA Sequencing

    PPM1D variants associated with Jansen-de Vries syndrome reported in the literature, in this case (red square), and in the ClinVar database to date ( https://www.ncbi.nlm.nih.gov/clinvar/ ). [1] ; [2] ; [3] ; [4] ; [5] ; [6] ; [7] ; [8] ; [9] ; [10] ; [11] ; [12] ; [13] ClinVar . Reference sequence NM_003620.4 .

    Journal: Frontiers in Genetics

    Article Title: Case Report: Novel truncating PPM1D variant in a dichorionic diamniotic (DCDA) twin with Jansen-de Vries syndrome. an updated perspective

    doi: 10.3389/fgene.2025.1601752

    Figure Lengend Snippet: PPM1D variants associated with Jansen-de Vries syndrome reported in the literature, in this case (red square), and in the ClinVar database to date ( https://www.ncbi.nlm.nih.gov/clinvar/ ). [1] ; [2] ; [3] ; [4] ; [5] ; [6] ; [7] ; [8] ; [9] ; [10] ; [11] ; [12] ; [13] ClinVar . Reference sequence NM_003620.4 .

    Article Snippet: Subsequent to this, we undertook massive parallel sequencing on a NextSeq550 instrument (Illumina).

    Techniques: Sequencing